Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Head and neck

Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma and non-adenoid cystic carcinoma

The purpose of this study is to look at the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer. Another purpose of the study is to see which tumor markers (proteins in the blood that the body produces in response to the cancer) lead to better results in participants treated with the study drugs.

Status: Accepting New Patients
Principal Investigator: Maria Matsangou

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

Carboplatin-Paclitaxel Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to see how safe and effective ABT-888 is, when combined with chemotherapy, at shrinking cancer.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin. Cisplatin is approved by the United States Food and Drug Administration (FDA) to be used with radiation therapy for the treatment of head and neck cancer.

Status: Accepting New Patients
Principal Investigator: Maria Matsangou

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Randomized Phase II Study of Sorafenib with or without Everolimus In Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer

The purpose of this study is to assess additional benefit of treating your cancer with the addition of Everolimus to Sorafenib and whether these two drugs together do not give serious and intolerable side effects. The addition of everolimus to the usual sorafenib might cause more shrinkage of your cancer and might prevent it from growing but it could also cause more side effects than sorafenib alone. This study will allow the researchers to know whether this treatment with 2 drugs is better, the same, or worse than the usual approach (which is sorafenib alone). To be better, the study drugs should increase the time it takes your cancer to progress by four and a half months or more compared to the usual approach. There will be about 56 people taking part in this study.

Status: Accepting New Patients
Principal Investigator: Maria Matsangou

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Randomized Phase II And Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

The main purpose of this study is to see if a longer progression free survival time for nasopharyngeal cancer can be obtained by individualizing treatment based on certain biomarkers.

Status: Accepting New Patients
Principal Investigator: Bharat Mittal

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone versus radiation therapy and cetuximab on head and neck cancer after surgery.

Status: Accepting New Patients
Principal Investigator: Bharat Mittal

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Wed - August 16, 2017 - 05:10 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.